human igg2

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Human IgG2 kappa Isotype Control is a monoclonal antibody serving as an isotype control specific to human IgG2κ antibodies [1].

Human IgG1 CH1-Human IgG2 Fc-Kappa Isotype control is the isotype control for Human IgG1 CH1+Human IgG2 Fc-Kappa antibody.

Human IgG2 lambda, Isotype Control, is a monoclonal antibody derived from humans and serves as the isotype control for the human IgG2λ antibody.

Figitumumab (CP-751871) is a highly potent, fully human monoclonal antibody of the IgG2 isotype that specifically targets the insulin-like growth factor 1 receptor (IGF1R). it functions by competitively inhibiting the binding of IGF1 to its receptor with a IC50 of 1.8 nM. Figitumumab can be used in studies about advanced squamous cell carcinoma of the lung.

Brodalumab (AMG 827) is a human monoclonal IgG2 antibody targeting the interleukin 17 receptor (IL-17R), commonly used as an immunosuppressant in treating psoriasis.

Tarextumab (OMP-59R5) is a fully human IgG2 monoclonal antibody designed to selectively target and inhibit the signaling of Notch2 and Notch3 receptors. preclinical and clinical studies have demonstrated that inhibition of the Notch2/3 pathway with chemotherapeutic agents is efficacious across a broad spectrum of epithelial tumors, including breast, lung, ovarian, and pancreatic cancers, thereby establishing Tarextumab as a promising candidate for oncological research and development.

Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1 with a Kd value of 7 nM for human ALK1. It has an inhibitory effect on TGF-β and can be used to study hepatocellular carcinoma (HCC).

Befovacimab (BAY 1093884), a fully human monoclonal IgG2 antibody, binds to the tissue factor pathway inhibitor (TFPI). It is utilized in research for haemophilia A B [1].

Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting in a decrease in LDL-C levels. Tafolecimab has potential applications in hypercholesterolemia research [1].

Eflepedocokin alfa is a recombinant fusion protein comprising human IL-22 fused with the human IgG2-Fc domain, exhibiting cell protective activity. It activates the IL-22 IL-22R-mediated signal transduction pathways, including STAT3, playing a critical role in immune response to bacterial infections. It enhances intestinal barrier function, boosts intestinal immunity, and facilitates tissue repair [1].

Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).

Prezalumab (AMG 557) is a human IgG2 monoclonal antibody targeting ICOSL and BAFF, used for studying Sjogren's syndrome, cutaneous lupus erythematosus, psoriasis, systemic lupus erythematosus arthritis, and systemic lupus erythematosus (SLE).

Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting the immunoglobulin-like domain-containing receptor 2 (ILDR2), and it exhibits antitumor and immunosuppressive effects [1].

Fulranumab (AMG-403) is a humanised monoclonal antibody targeting nerve growth factor (NGF), which blocks the binding and activation of NGF with TrkA and p75NTR and has analgesic effects, and can be used for the study of chronic pain.

RG-6125 is a humanized antibody expressed in CHO cells, targeting CDH11 Cadherin-11. It features a huIgG2 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145 kDa. For an isotype control, please refer to HumanIgG2kappa, Isotype Control.

AMG-820 is a human antibody targeting CSF-1R, inhibiting the binding of ligands CSF1 and IL34, and preventing subsequent ligand-induced receptor activation. For AMG-820's isotype control, refer to [Human IgG2 kappa, Isotype Control].

M6903 is a humanized IgG2 monoclonal antibody that targets T-cell immunoglobulin and mucin domain 3 (TIM-3), with a binding affinity (KD) of 2.3 nM for human TIM-3. By binding to TIM-3, M6903 blocks the interaction of TIM-3 with phosphatidylserine (PtdSer), carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), and galectin-9 (Gal-9). This blockade helps alleviate TIM-3-mediated T-cell inhibition, promoting antigen-specific T-cell activation and enhancing antitumor immunity. M6903 holds promise for cancer research.